Clinical Trial Update: Intervention of Engineered Immune Effector T Cells Against Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

The Phase 1/Phase 2 trial of engineered immune effector T cells for lung cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Non-small Cell Lung Cancer

Snippet

Sponsor: Shenzhen Geno-Immune Medical Institute | Conditions: Lung Cancer, NSCLC | Phase 1, Phase 2 | Status: WITHDRAWN